Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
Details:
Secukinumab is a antibody candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Psoriasis.
Lead Product(s): Secukinumab,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 28, 2025
Lead Product(s) : Secukinumab,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Secukinumab is a antibody candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 28, 2025
Details:
Methotrexate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Rheumatic Diseases.
Lead Product(s):
Methotrexate,Sulfasalazine,Hydroxychloroquine Sulphate,Leflunomide,Azathioprine,Mycophenolic Acid,Cyclosporine,Tacrolimus,
Therapeutic Area: Rheumatology
Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cytotoxic Drug Sponsor:
Undisclosed
Deal Size: Inapplicable
Upfront Cash: Inapplicable
Deal Type: Inapplicable
August 24, 2025
Lead Product(s) : Methotrexate, Sulfasalazine, Hydroxychloroquine Sulphate, Leflunomide, Azathioprine
Therapeutic Area : Rheumatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunosuppressant Management in Rheumatology Patients Undergoing Shoulder Arthroplasty
Details : Methotrexate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Rheumatic Diseases.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
August 24, 2025
Details:
Secukinumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Juvenile.
Lead Product(s): Secukinumab,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 27, 2024
Lead Product(s) : Secukinumab,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Secukinumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Juvenile.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 27, 2024
Details:
Secukinumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Lead Product(s): Secukinumab,Ixekizumab,Guselkumab
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: Belgium Health Care Knowledge Centre
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 03, 2024
Lead Product(s) : Secukinumab,Ixekizumab,Guselkumab
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Belgium Health Care Knowledge Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Proactive TDM Versus Standard Use of Biologics in Psoriasis
Details : Secukinumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 03, 2024
Details:
Secukinumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polymyalgia Rheumatica.
Lead Product(s): Secukinumab,Inapplicable
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 26, 2024
Lead Product(s) : Secukinumab,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Details : Secukinumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polymyalgia Rheumatica.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 26, 2024
Details:
Secukinumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Giant Cell Arteritis.
Lead Product(s): Secukinumab,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 14, 2023
Lead Product(s) : Secukinumab,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Secukinumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Giant Cell Arteritis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 14, 2023
Details:
Cosentyx (secukinumab) is a biologic that inhibits interleukin-17A, a cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis and axial spondyloarthritis. Now it is approved for hidradenitis suppurativa.
Lead Product(s): Secukinumab,Inapplicable
Therapeutic Area: Dermatology Brand Name: Cosentyx
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 31, 2023
Lead Product(s) : Secukinumab,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Novartis Cosentyx® as The First New Biologic Treatment Option for Hidradenitis Suppu...
Details : Cosentyx (secukinumab) is a biologic that inhibits interleukin-17A, a cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis and axial spondyloarthritis. Now it is approved for hidradenit...
Product Name : Cosentyx
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 31, 2023
Details:
Cosentyx (secukinumab) is an interleukin-17A (IL-17A) inhibitor, previously approved for psoriatic arthritis, plaque psoriasis, ankylosing spondylitis & axial spondyloarthritis. It is now approved for hidradenitis suppurativa.
Lead Product(s): Secukinumab,Inapplicable
Therapeutic Area: Dermatology Brand Name: Cosentyx
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 31, 2023
Lead Product(s) : Secukinumab,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Novartis Cosentyx® as the First New Biologic Treatment Option for Hidradenitis Suppu...
Details : Cosentyx (secukinumab) is an interleukin-17A (IL-17A) inhibitor, previously approved for psoriatic arthritis, plaque psoriasis, ankylosing spondylitis & axial spondyloarthritis. It is now approved for hidradenitis suppurativa.
Product Name : Cosentyx
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 31, 2023
Details:
Cosentyx (secukinumab) is an intravenous formulation that specifically targets and blocks interleukin-17A (IL-17A), which is indicated for the treatment of rheumatic diseases.
Lead Product(s): Secukinumab,Inapplicable
Therapeutic Area: Immunology Brand Name: Cosentyx
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 06, 2023
Lead Product(s) : Secukinumab,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Novartis Cosentyx® as First Intravenous (IV) Formulation Interleukin-17A Antagonist ...
Details : Cosentyx (secukinumab) is an intravenous formulation that specifically targets and blocks interleukin-17A (IL-17A), which is indicated for the treatment of rheumatic diseases.
Product Name : Cosentyx
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 06, 2023
Details:
Cosentyx (secukinumab) is the USFDA approved, human biologic that directly inhibits interleukin-17A and received European approval for for hidradenitis suppurativa.
Lead Product(s): Secukinumab,Inapplicable
Therapeutic Area: Dermatology Brand Name: Cosentyx
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 01, 2023
Lead Product(s) : Secukinumab,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cosentyx (secukinumab) is the USFDA approved, human biologic that directly inhibits interleukin-17A and received European approval for for hidradenitis suppurativa.
Product Name : Cosentyx
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 01, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : USA
Brand Name : COSENTYX
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 150MG/ML
Packaging :
Approval Date :
Application Number : 125504
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : USA
Brand Name : COSENTYX
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number : 761349
Regulatory Info :
Registration Country : USA
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Cosentyx powder for solution for injection
Dosage Form : Injectable Solution
Dosage Strength : 150mg
Packaging :
Approval Date : 20/02/2015
Application Number : 63295
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Cosentyx
Dosage Form : Solution For Injection
Dosage Strength : 150mg/ml
Packaging :
Approval Date : 20/02/2015
Application Number : 65225
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Cosentyx
Dosage Form : Solution For Injection
Dosage Strength : 300mg/2ml
Packaging :
Approval Date : 20/02/2015
Application Number : 65225
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Cosentyx
Dosage Form : Solution For Injection
Dosage Strength : 75mg/0.5ml
Packaging :
Approval Date : 20/02/2015
Application Number : 65225
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Cosentyx SensoReady
Dosage Form : Solution For Injection
Dosage Strength : 150mg/ml
Packaging :
Approval Date : 20/02/2015
Application Number : 65226
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Cosentyx UnoReady
Dosage Form : Solution For Injection
Dosage Strength : 300mg/2ml
Packaging :
Approval Date : 03/02/2022
Application Number : 68324
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Cosentyx
Dosage Form : Solution For Injection
Dosage Strength : 150mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Cosentyx
Dosage Form : Solution For Injection
Dosage Strength : 300mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gloria Interchem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Solubilizers
Parenteral
Thickeners and Stabilizers
Surfactant & Foaming Agents
Emulsifying Agents
Topical
Film Formers & Plasticizers
API Stability Enhancers
Co-Processed Excipients
Taste Masking
Direct Compression
Rheology Modifiers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
